First IPF Biomarker Clears Initial FDA Step Toward Qualification

IPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial ...
Everyday Health on MSN

Weather and your lungs: How temperature and humidity affect IPF symptoms

Discover how weather conditions affect idiopathic pulmonary fibrosis (IPF) symptoms and learn practical tips to manage your ...
The American Journal of Managed Care

Multi-Stakeholder Collaboration Is Essential to Achieve Equity in IPF Care

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet ...
The American Journal of Managed Care

Anti-Fibrotic Nerandomilast Proves Tolerable Compared With Other IPF/PPF Drugs

Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, showed sustained efficacy in the FIBRONEER trials for IPF and PPF, achieving ...
Healthline

6 Hidden IPF Warning Signs

Idiopathic pulmonary fibrosis (IPF) is a rare and chronic lung condition. The word “idiopathic” means there’s no known cause of the condition, which can make diagnosing it difficult. A hacking cough ...
European Medical Journal

Immune Signature Predicts Survival in Idiopathic Pulmonary Fibrosis

New research identifies a specific monocyte gene signature that predicts mortality in IPF, offering potential targets ...
Fierce Pharma

BI's Jascayd quickly expands lung disease reach with new FDA nod

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...
Healio

Phase 1 trial of potential treatment for IPF moves forward ‘without any safety concerns’

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prior to this trial, CS014 had positive outcomes in an ...
FierceBiotech

Taking on pharma giants, Endeavor links IPF drug to improved lung function in phase 2

Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic pulse through a sector currently dominated by ...
Healio

Q&A: Investigational therapy shows potential for treating patients with IPF

Please provide your email address to receive an email when new articles are posted on . Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved ...
Kaleido Scope

Research points to possible target to treat idiopathic pulmonary fibrosis, or IPF

Long-held dogma says lung fibrosis in diseases like idiopathic pulmonary fibrosis, or IPF, results from recurrent injury to alveolar epithelium that is followed by dysregulated repair. Research at the ...
TipRanks on MSN

IPF extends deadline for BasePoint’s potential acquisition offer

International Personal Finance ( ($GB:IPF) ) has shared an announcement. International Personal Finance Plc (IPF) has announced an extension of ...